Last reviewed · How we verify
PVC (twice weekly)
PVC (twice weekly) is a Antiarrhythmic Small molecule drug developed by Wyeth is now a wholly owned subsidiary of Pfizer. It is currently in Phase 3 development for Prevention of recurrent symptomatic supraventricular tachycardia.
PVC works by blocking the action of certain electrical signals in the heart, helping to regulate its rhythm.
PVC, also known as Olopatadine, is a small molecule used in various medical studies, including those for Fecal Incontinence, Encopresis, and Oral Cancer. It has been studied in combination with traditional treatment, biofeedback, and electrical stimulation, but its exact mechanism of action is not specified in the provided information.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care. -
Big-pharma sponsor
+3.0pp
Wyeth is now a wholly owned subsidiary of Pfizer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | PVC (twice weekly) |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Drug class | Antiarrhythmic |
| Target | AV node, bundle of His |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
PVC achieves this by targeting the heart's electrical conduction system, specifically the atrioventricular (AV) node and the bundle of His. This helps to prevent abnormal heart rhythms and reduce the risk of complications such as stroke and heart failure.
Approved indications
- Prevention of recurrent symptomatic supraventricular tachycardia
Common side effects
- Dizziness
- Headache
- Nausea
- Fatigue
Key clinical trials
- Upfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers: (PHASE3)
- Biofeedback Training Fecal Incontinence in Children (NA)
- Biofeedback Vs Electrical Stimulation in Treatment of Fecal Incontinence (NA)
- Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PVC (twice weekly) CI brief — competitive landscape report
- PVC (twice weekly) updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI
Frequently asked questions about PVC (twice weekly)
What is PVC (twice weekly)?
How does PVC (twice weekly) work?
What is PVC (twice weekly) used for?
Who makes PVC (twice weekly)?
What drug class is PVC (twice weekly) in?
What development phase is PVC (twice weekly) in?
What are the side effects of PVC (twice weekly)?
What does PVC (twice weekly) target?
Related
- Drug class: All Antiarrhythmic drugs
- Target: All drugs targeting AV node, bundle of His
- Manufacturer: Wyeth is now a wholly owned subsidiary of Pfizer — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Prevention of recurrent symptomatic supraventricular tachycardia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing